Document:

Exhibit 4.2

 

NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.  

 

	No. [N-__]	[______], 2020

 

NeuroOne
Medical Technologies Corporation

 

Common
Stock Purchase Warrant

 

_________________

 

This
Certifies That, for value received, [________________], or his/her/its
registered assigns (the “Holder”), is entitled to subscribe for and purchase from NeuroOne
Medical Technologies Corporation, a Delaware corporation (the “Company”), at any time commencing
on [______], 2020 and expiring on [                   ] (such period, the “Warrant Exercise
Term”), the Shares at the Exercise Price (each as defined in Section 1 below).

 

This Warrant (this
“Warrant”) is issued in connection with the issuance of the Holder’s 13% convertible promissory
note (the “Note”), pursuant to Section 3.1(f) of the Note. Capitalized terms used
and not otherwise defined herein shall have the respective meanings assigned to such terms in the Note.

 

This Warrant is subject
to the following terms and conditions:

 

1. Shares.
The Holder has, subject to the terms set forth herein, the right to purchase, at any time during the Warrant Exercise Term, up
to [________________]  shares of Company’s common stock, par value $0.001 per
share (the “Common Stock”), at a per share exercise price of $1.87 (as the same may be adjusted as provided
in Section 3 hereof, the “Exercise Price”). The shares of Common Stock received upon any exercise
of this Warrant are referred to herein as the “Shares”.

 

     

     

    

 

2. Exercise
of Warrant. 

 

(a) Exercise.
This Warrant may be exercised by the Holder at any time during the Warrant Exercise Term, in whole or in part, by delivering to
the Company at its principal office, or at such other office as the Company may designate (i) the notice of exercise attached as
Exhibit A hereto (the “Notice of Exercise”), duly
executed by the Holder and (ii) this Warrant certificate, accompanied by (iii) payment, in cash or by wire transfer of immediately
available funds or by check payable to the order of the Company of the amount obtained by multiplying the number of Shares designated
in the Notice of Exercise by the Exercise Price (the “Purchase Price”). For purposes hereof, “Exercise
Date” shall mean the date on which all deliveries required to be made to the Company upon exercise of this Warrant
pursuant to this Section 2(a) shall have been made. In no event shall the Company be required to net cash settle any Warrant
exercise.

 

(b) Redemption.

 

(i)All
of the outstanding Warrants (but not less than all) may be redeemed, at the option of the Company, at any time beginning after
the one-year anniversary of the date hereof and during the Warrant Exercise Term upon notice to the Holder at the price of $4.00
per Warrant (the “Redemption Price”), provided that the VWAP (as defined below) of the Common Stock is
at least 200% of the Exercise Price for 20 consecutive Trading Days immediately prior to both (A) the date on which notice of redemption
is give and (B) the Redemption Date (defined below). “VWAP” means, for any date, the price determined
by the first of the following clauses that applies: (A) if the Common Stock is then listed or quoted on a Trading Market (other
than the OTC Bulletin Board or OTC Markets, Inc.), the daily volume weighted average price of the Common Stock for such date (or
the nearest preceding Trading Day) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg
L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (B) if the Common Stock is
then quoted on the OTC Bulletin Board, the volume weighted average price of the Common Stock for such date (or the nearest preceding
Trading Day) on the OTC Bulletin Board, (C) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board
and if prices for the Common Stock are then reported on OTC Markets, Inc. (or a similar organization or agency succeeding to its
functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (D) in all other cases,
the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders
of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company. “Trading Day” means a day on which the principal Trading Market is open
for trading. “Trading Market” means any of the following markets or exchanges on which the Common Stock
is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market, the New York Stock Exchange (or any successors to any of the foregoing), the OTC Bulletin Board or
OTC Markets, Inc.

 

(ii)The
Company shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be mailed
by first class mail, postage prepaid, by the Company not less than 30 days prior to the Redemption Date to the Holders to
be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided
shall be conclusively presumed to have been duly given whether or not the Holder received such notice.

 

(iii)The
notice of redemption shall contain the information necessary to calculate the number of Shares to be received upon exercise of
the Warrants, including the VWAP calculations. On and after the Redemption Date, the record holder of the Warrants shall have no
further rights except to receive, upon surrender of the Warrants, the Redemption Price.

 

    2

     

    

  

(c) Issuance
of Shares. As soon as practicable after the exercise of this Warrant, in whole or in part, in accordance with Section 2(a)
hereof, the Company, at its expense, shall cause to be issued in the name of and delivered to the Holder (i) written confirmation
that the Shares have been issued in the name of the Holder, and (ii) a new warrant of like tenor to purchase all of the Shares
that may be purchased pursuant to the portion, if any, of this Warrant not exercised by the Holder.

 

3. Adjustment
of Exercise Price and Number of Shares. 

 

(a) Adjustment
for Reclassification, Consolidation or Merger. If while this Warrant, or any portion hereof, remains outstanding and unexpired
there shall be (i) a reorganization or recapitalization (other than a combination, reclassification, exchange or subdivision of
shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation or other
entity in which the Company shall not be the surviving entity, or a reverse merger in which the Company shall be the surviving
entity but the shares of the Company’s capital stock outstanding immediately prior to the merger are converted by virtue
of the merger into other property, whether in the form of securities, cash or otherwise, or (iii) a sale or transfer of the Company’s
properties and assets as, or substantially as, an entirety to any other corporation or other entity in one transaction or a series
of related transactions, then, as a part of such reorganization, recapitalization, merger, consolidation, sale or transfer, unless
otherwise directed by the Holder, all necessary or appropriate lawful provisions shall be made so that the Holder shall thereafter
be entitled to receive upon exercise of this Warrant during the Warrant Exercise Term and upon payment of the Exercise Price then
in effect, the greatest number of shares of capital stock or other securities or property that a holder of the Shares deliverable
upon exercise of this Warrant would have been entitled to receive in such reorganization, recapitalization, merger, consolidation,
sale or transfer if this Warrant had been exercised immediately prior to such reorganization, recapitalization, merger, consolidation,
sale or transfer, all subject to further adjustment as provided in this Section 3. If the per share consideration payable
to the Holder for Shares in connection with any such transaction is in a form other than cash or marketable securities, then the
value of such consideration shall be determined in good faith by the Board. The foregoing provisions of this paragraph shall similarly
apply to successive reorganizations, recapitalizations, mergers, consolidations, sales and transfers and to the capital stock or
securities of any other corporation that are at the time receivable upon the exercise of this Warrant. In all events, appropriate
adjustment shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder
after the transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably
may be, in relation to any shares or other property deliverable or issuable after such reorganization, recapitalization, merger,
consolidation, sale or transfer upon exercise of this Warrant.

 

(b) Adjustments
for Split, Subdivision or Combination of Shares. If the Company shall at any time subdivide (by any stock split, stock dividend,
recapitalization, reorganization, reclassification or otherwise) the shares of Common Stock subject to acquisition hereunder, then,
after the date of record for effecting such subdivision, the Exercise Price in effect immediately prior to such subdivision will
be proportionately reduced and the number of shares of Common Stock subject to acquisition upon exercise of the Warrant will be
proportionately increased. If the Company at any time combines (by reverse stock split, recapitalization, reorganization, reclassification
or otherwise) the shares of Common Stock subject to acquisition hereunder, then, after the record date for effecting such combination,
the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of shares of
Common Stock subject to acquisition upon exercise of the Warrant will be proportionately decreased.

 

    3

     

    

  

(c) Adjustments
for Dividends in Stock or Other Securities or Property. If while this Warrant, or any portion hereof, remains outstanding and
unexpired, the holders of any class of securities as to which purchase rights under this Warrant exist at the time shall have received
or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without
payment therefor, other or additional stock or other securities or property (other than cash) of the Company by way of dividend,
then and in each case, this Warrant shall represent the right to acquire, in addition to the number of shares of such class of
security receivable upon exercise of this Warrant, and without payment of any additional consideration therefor, the amount of
such other or additional stock or other securities or property (other than cash) of the Company that such holder would be entitled
to receive had it been the holder of record of the class of security receivable upon exercise of this Warrant on the record date
fixed for the determination of stockholders eligible to receive such dividend, giving effect to all adjustments called for by the
provisions of this Section 3 that occur from such record date to the date of such exercise.

 

(d) [Reserved.]

 

(e) Notice
of Adjustments. Upon any adjustment of the Exercise Price and any increase or decrease in the number of Shares purchasable
upon the exercise of this Warrant, then, and in each such case, the Company, within 30 days thereafter, shall give written notice
thereof to the Holder at the address of such Holder as shown on the books of the Company, which notice shall state the Exercise
Price as adjusted and, if applicable, the increased or decreased number of Shares purchasable upon the exercise of this Warrant,
setting forth in reasonable detail the method of calculation of each. The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this Section 3, following any adjustment hereunder, the number
of Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. 

 

4. Transfer
of Warrant. 

 

(a) Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and
under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or
current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, comply with certain transfer restrictions.

 

(b) Holder
Representation. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Shares issuable upon such exercise, for its own account and not with a view to or for distributing
or reselling such Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except
pursuant to sales registered or exempted under the Securities Act.

 

    4

     

    

 

5.
 Notices. Any and all notices or other communications or deliveries required
or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date
of transmission, if such notice or communication is delivered via e-mail transmission prior to 5:00 P.M., New York City time, on
a trading day, (b) the next trading day after the date of transmission, if such notice or communication is delivered via e-mail
transmission on a day that is not a trading day or later than 5:00 P.M., New York City time, on any trading day, (c) the trading
day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified,
or (d) upon actual receipt by the party to whom such notice is required to be given. The address and e-mail address for such notices
and communications shall be as follows:

 

If to the Company to:

 

NeuroOne Medical Technologies Corporation

7599 Anagram Drive

Eden Prairie, MN 55344

Attention: David A. Rosa

Email: daver@n1mtc.com

 

With a copy (that shall not constitute notice)
to:

 

Honigman LLP

650 Trade Centre Way Suite 200

Portage, Michigan 49002

Attention: Phillip D. Torrence

Facsimile: (269) 337-7703

Email: ptorrence@honigman.com

 

If to the Holder
at its address or e-mail address as furnished in that certain subscription agreement entered into between the Holder and the Company
in connection with Holder’s purchase of the Note.

 

Either party may give
any notice, request, consent or other communication under this Warrant using any other means, but no such notice, request, consent
or other communication shall be deemed to have been duly given unless and until it is actually received by the party for whom it
is intended. Either party may change the address to which notices, requests, consents or other communications hereunder are to
be delivered by giving the other party notice in the manner set forth in this Section 5.

 

6. Legends.
The Holder acknowledges that each certificate evidencing the Shares acquired upon the exercise of this Warrant will
have restrictions upon resale imposed by state and federal securities laws. Each such certificate shall be stamped or imprinted
with a legend substantially in the following form:

 

THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS
OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL
AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

    5

     

    

  

8. Fractional
Shares. No fractional Shares will be issued in connection with any exercise hereunder. Instead, the Company shall round
the number of Shares to be issued up to the nearest whole Share. This Warrant may only be exercised for whole shares.

 

9. Rights
of Stockholders. Except as expressly provided in Section 3(c) hereof, the Holder, as such, shall not be entitled
to vote or receive dividends or be deemed the holder of the Shares or any other securities of the Company that may at any time
be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder,
as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter
submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization,
issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive
notice of meetings, or otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof
shall have been issued, as provided herein.

 

10. Miscellaneous.

 

(a) All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Note. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable
law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of
such provisions or the remaining provisions of this Warrant.

 

(b) The
headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

(c) The
terms of this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns of the Company
and of the Holder and of the Shares issued or issuable upon the exercise hereof.

 

(d) This
Warrant and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
parties with regard to the subject hereof.

 

(e) The
Company shall not, by amendment of the certificate of incorporation or bylaws, or through any other means, directly or indirectly,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times in good faith assist
in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect
the rights of the Holder contained herein against impairment.

 

    6

     

    

 

(f) Upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in
the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount
to the Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company, at its expense,
will execute and deliver to the Holder, in lieu thereof, a new Warrant of like date and tenor.

 

(g) This
Warrant and any provision hereof may be amended, waived or terminated only by the written consent of the Company and the holders
of a majority of the shares underlying the units received by investors in the conversion of the Series 3 Notes.

 

signature
page follows 

 

    7

     

    

 

In
Witness Whereof, the Company has caused this Warrant to be signed by its duly authorized officer.

 

	 	NeuroOne Medical Technologies Corporation
	 	 	 
	 	By:	 
	 	Name:	David A. Rosa
	 	Title:	Chief Executive Officer

  

Signature
Page to

Common Stock Purchase Warrant

 

     

     

    

 

Exhibit
A

 

NOTICE OF EXERCISE

 

		To:	NeuroOne Medical Technologies Corporation

 

(1) The
undersigned hereby elects to purchase ________ Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any, in the
form of cash in lawful money of the United States.

 

(2) Please
issue said Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Shares shall be delivered to the following DWAC Account
Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(3) The undersigned is
an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[Holder]

 

Name of Investing Entity: ______________________________________________________________

Signature of Authorized Signatory of Investing Entity:
________________________________________

Name of Authorized Signatory: __________________________________________________________

Title of Authorized Signatory: ___________________________________________________________

Date: _______________________________________________________________________________

 

     

     

    

 

ASSIGNMENT FORM

 

(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	______________________________________
	 	(Please Print)
	 	 
	Address:	______________________________________
	 	(Please Print)
	 	 
	Phone Number:	______________________________________
	 	 
	Email Address: 	______________________________________
	 	 
	Dated: _______________ __, ______	 
	 	 
	Holder’s Signature:	 
	 	 
	Holder’s Address:Exhibit 10.1

 

SUBSCRIPTION
AGREEMENT

 

This
Subscription Agreement (this “Agreement”) is made
as of _________________ by and among NeuroOne Medical Technologies Corporation,
a Delaware corporation (the “Company”), and the subscribers identified on the signature pages
hereto (each, a “Subscriber” and collectively, the “Subscribers”).

 

Recitals

Whereas,
the Company seeks to sell a maximum of $3,000,000 (or such higher amount as the Company’s Board of Directors shall determine)
(the “Total Amount”) in Convertible Promissory Notes in the form annexed hereto as Exhibit
B (each, a “Note” and collectively, the “Notes”) and, subject to
Section 1.1 below, Warrants to purchase shares of the Company’s common stock as provided in the Note and in the form
of warrant agreement annexed hereto as Exhibit C (each, a “Warrant”
and collectively, the “Warrants”) pursuant to Section 4(a)(2) of the Securities Act of 1933,
as amended (the “Securities Act”), and Rule 506(b) of Regulation D (“Regulation D”)
as promulgated under the Securities Act (the “Offering”);

 

Whereas,
each Subscriber wishes to purchase a Note with the principal amount as set forth on such subscriber’s respective Signature
Page to this Agreement; and

 

Now,
Therefore, in consideration of the mutual covenants contained in this Agreement,
and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the
Subscribers hereby agree as follows: 

 

1. PURCHASE
OF CONVERTIBLE PROMISSORY NOTES.

 

1.1 Subscription.
Each Subscriber hereby subscribes (the “Subscription”) to purchase a Note in the amount set
forth on such Subscriber’s respective signature page hereto (the “Subscription Amount”). This
Subscription shall become effective when (a) it has been duly executed by the Subscriber, (b) this Agreement has been accepted
and agreed to by the Company and (c) the Company has effectuated a Closing as set forth in Section 1.5 hereof. Each Subscriber
shall be entitled to receive a Warrant as provided in such Subscriber’s Note.

 

The
Notes and Warrants are being offered by the Company and Paulson Investment Company, LLC (the “Placement Agent”).
The minimum purchase amount is $25,000, although the Company and Placement Agent may, in their discretion, accept subscriptions
for a lesser amount. The Placement Agent will receive a cash commission equal to 12% of the gross proceeds from the sale of the
Notes (the “Commission”). In addition to the Placement Agent’s Commission, the Company will issue
7-year warrants to the Placement Agent to purchase an amount of the Company’s common stock, par value $0.001 per share (“Common
Stock”), equal to 15% of the gross proceeds from the sale of the Notes.

 

    1

     

    

 

1.2 Payment
for Subscription. Each Subscriber agrees that the Subscription Amount to the Company for the amount of the Subscriber’s
Subscription is to be made upon submission of this Agreement in the form included in these Subscription Documents (as hereinafter
defined) by check or by wire transfer to an account designated by the Company. In the event that the Company does not sell the
Minimum Amount on or before July 31, 2020, which period may be extended by the Company, in its discretion to a date no later than
a maximum of 90 days until the Total Amount is reached, the Company will refund all subscription funds to the Subscriber, without
deduction, offset and/or interest accrued thereon, and the subscription documents. If the Company rejects a subscription, either
in whole or in part (which decision is in their sole discretion), the rejected subscription funds or the rejected portion thereof
will be returned promptly to the Subscriber without interest accrued thereon.

 

1.3 Deposit
of Funds. The Company shall hold all funds in escrow until such time as it closes on the corresponding subscriptions.
If the Company rejects a subscription, either in whole or in part (which decision is in their sole discretion), the rejected subscription
funds or the rejected portion thereof will be returned promptly to the Subscriber without interest accrued thereon.

 

1.4 Terms
and Conditions. The Company shall have the right to accept or reject a Subscription, in whole or in part, for any reason
whatsoever, including, but not limited to, the belief of the Company that a Subscriber cannot bear the economic risk of an investment
in the Company, is not capable of evaluating the merits and risks of an investment in the Company or is not an “Accredited
Investor,” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act, or for no reason at
all.

 

1.5 Closing.
A closing may occur once a Subscription is received by the Company and additional closings under the Offering may take
place from time to time as subscriptions are received by the Company.

 

(a) The
closing of the Subscriptions for the Notes and Warrants shall occur in one or more closings (collectively, the “Closings”
and each, without distinction, a “Closing”). Each Closing shall be held remotely by the electronic
exchange of documents and funds, at 10:00 a.m. Eastern Time, or at such other time and by such means upon which the Company and
the Subscribers purchasing the Notes at such Closing shall agree.

 

(b) The
first such Closing (the “Initial Closing”) for an aggregate amount of at least $25,000 in Principal
Amount of Notes (the “Minimum Amount”) shall take place on a date determined by the Company within 10
days of the date upon which the Company shall have received Subscriptions having an aggregate principal amount equal to the Minimum
Amount. The Notes and Warrants issued at the Initial Closing shall be documented in a Schedule of Purchasers maintained by the
Company (the “Schedule of Purchasers”).

 

(c) At
any time after the Initial Closing, to the extent that (i) Subscribers already party to this Agreement and/or additional Subscribers
agree by execution of a signature page hereto to purchase an aggregate amount of at least $25,000 in additional principal amount
of Notes, up to a balance of the Total Amount, the Company shall, within 10 days thereafter, hold an additional Closing with respect
to the purchase of such Notes (each, a “Subsequent Closing”); provided, however, that the aggregate
purchase price of Notes issued at the Initial Closing and all Subsequent Closings may not exceed the Total Amount unless otherwise
approved by the Company’s Board of Directors. Other than expressly provided above in this Section 1.5(c), there shall
be no conditions precedent to a Subsequent Closing. Upon each Subsequent Closing, the Company shall amend the Schedule of Purchasers.
The terms of the transactions consummated at each Subsequent Closing shall be identical to the terms of the transactions consummated
at the Initial Closing, excepting the date of issuance of the Notes shall be the date of such Subsequent Closing. The Notes issued
in each Subsequent Closing shall be issued to the Subscribers in the principal amount shown for each Subscriber with respect to
such Subsequent Closing on the amended Schedule of Purchasers.

 

    2

     

    

 

(d) At
each Closing, the Company shall deliver to the Subscribers copies of the executed Notes for the Subscription Amount, and shall
deliver to the Subscribers the original executed Notes as soon as recently practicable following the final Closing of the Offering.

 

2. REPRESENTATIONS
AND WARRANTIES.

 

2.1 Representations
and Warranties by the Company. The Company represents and warrants to each Subscriber, except as and to the extent
set forth in the publicly available reports, schedules, forms, statements and other documents filed by the Company with, or furnished
by the Company to, the Securities and Exchange Commission (“SEC”) on or after July 20, 2017 and before
the trading day immediately prior to the date hereof (the “SEC Reports”), to the extent the relevance
of the disclosure is reasonably apparent, as follows, in each case as of the date hereof and as of each Closing:

 

(a) Authorization.
The Company has all corporate right, power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the: (i) authorization execution,
delivery and performance of this Agreement by the Company; (ii) authorization, sale, issuance and delivery of the Notes and Warrants
contemplated hereby and the performance of the Company’s obligations hereunder; and (iii) authorization, issuance and delivery
of the securities issuable upon conversion of the Notes or exercise of the Warrants, has been taken. The securities issuable upon
conversion of the Notes and exercise of the Warrants will be validly issued, fully paid and nonassessable. The issuance and sale
of the securities contemplated hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any
person which have not been waived in connection with this Offering. The Company is not in default of any other obligations, including
any promissory notes or debentures.

 

(b) Enforceability.
Assuming this Agreement has been duly and validly authorized, executed and delivered by the parties hereto and thereto other
than the Company, this Agreement is duly authorized, executed and delivered by the Company and constitutes the legal, valid and
binding obligations of the Company enforceable against the Company in accordance with its terms, except as such enforcement is
limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors
rights generally.

 

(c) No
Violations. The execution, delivery and performance of this Agreement and the Note by the Company and the consummation by
the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Warrants and
the securities issuable upon the conversion of the Note or exercise of the Warrants) will not (i) result in a violation of the
Certificate of Incorporation of the Company or other organizational documents of the Company, (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable to the Company by which any
property or asset of the Company is bound or affected.

 

    3

     

    

 

(d) Litigation.
(i) The Company knows of no pending or threatened legal or governmental proceedings against the Company which could materially
adversely affect the business, property, financial condition or operations of the Company or which materially and adversely questions
the validity of this Agreement or any agreements related to the transactions contemplated hereby or the right of the Company to
enter into any of such agreements, or to consummate the transactions contemplated hereby or thereby. The Company is not a party
or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality
which could materially adversely affect the business, property, financial condition or operations of the Company. There is no
action, suit, proceeding or investigation by the Company currently pending in any court or before any arbitrator or that the Company
intends to initiate.

 

(ii) There
is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investigation, proceeding
or demand letter pending, or to the knowledge of the Company threatened, against the Company, which if adversely determined would
reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations hereunder. There
is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investigation, proceeding
or demand letter pending, or to the knowledge of the Company threatened, against or affecting the Company or any of its subsidiaries
that, if adversely determined, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries
(taken as a whole). There are no outstanding orders, writs, judgments, decrees, injunctions or settlements that would reasonably
be expected to have a material adverse effect on the Company and its subsidiaries (taken as a whole).

 

(e) Intellectual
Property. The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights,
trade secrets, licenses, information and other proprietary rights and processes necessary for its business as now conducted without
any known infringement of the rights of others. The Company has not received any written communications alleging that the Company
has violated or, by conducting its business as presently proposed to be conducted, would violate any of the patents, trademarks,
service marks, trade names, copyrights or trade secrets or other proprietary rights of any other person or entity.

 

(f) Title
to Assets. The Company has good and marketable title to its properties and assets, and good title to its leasehold estates,
in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than (i) those resulting from taxes which
have not yet become delinquent; (ii) liens and encumbrances which do not materially detract from the value of the property subject
thereto or materially impair the operations of the Company; and (iii) those that have otherwise arisen in the ordinary course
of business. The Company is in compliance with all material terms of each lease to which it is a party or is otherwise bound.

 

    4

     

    

 

(g) Investment
Company. The Company is not an “investment company” within the meaning of such term under the Investment Company
Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 

(h) No
Solicitation. Neither the Company nor any person participating on the Company’s behalf in the transactions contemplated
hereby has conducted any “general solicitation,” as such term is defined in Regulation D promulgated under the Securities
Act, with respect to any of the Notes being offered hereby.

 

(i) Blue
Sky. The Company agrees to file a Form D with respect to the sale of the Notes under Regulation D of the rules and regulations
promulgated under the Securities Act. The Company shall take such action as the Company shall reasonably determine is necessary
to qualify the Notes for sale to the Subscriber pursuant to this Agreement under applicable securities or “blue sky”
laws of the states of the United States (or to obtain an exemption from such qualification).

 

(j) Non-Contravention.
The execution, delivery and performance of this Agreement by the Company will not (i) violate any law, treaty, rule or regulation
applicable to or binding upon the Company or any of its properties or assets, or (ii) result in a breach of any contractual obligation
to which the Company is a party or by which it or any of its properties or assets is bound that would reasonably be expected to
have a material adverse effect on the ability of the Company to perform its obligations under this Agreement.

 

2.2 Survival
of Representations and Warranties. The representations and warranties of the Company shall survive the Initial Closing
for a period of 12 months and shall be fully enforceable at law or in equity against the Company and the Company’s successors
and assigns.

 

2.3 Disclaimer.
It is specifically understood and agreed by each Subscriber that the Company has not made, nor by this Agreement shall
be construed to make, directly or indirectly, explicitly or by implication, any representation, warranty, projection, assumption,
promise, covenant, opinion, recommendation or other statement of any kind or nature with respect to the anticipated profits or
losses of the Company, except as otherwise provided with this Agreement.

 

2.4 Representations
and Warranties by the Subscribers. Each Subscriber represents and warrants to the Company, as of the date hereof and
as of each Closing, as follows:

 

(a) The
Subscriber is acquiring the Notes and the Warrants for the Subscriber’s own account, as principal, for investment purposes
only and not with any intention to resell, distribute or otherwise dispose of the Notes or Warrants, as the case may be, in whole
or in part.

 

    5

     

    

 

(b) The
Subscriber has had an unrestricted opportunity to: (i) obtain information concerning the Offering, including the Notes, the Warrants,
the Company and its proposed and existing business and assets; and (ii) ask questions of, and receive answers from the Company
concerning the terms and conditions of the Offering and to obtain such additional information as may have been necessary to verify
the accuracy of the information contained in the this Agreement or otherwise provided. Such Subscriber acknowledges receipt of
copies of the SEC Reports (or access thereto via EDGAR). Neither such inquiries nor any other due diligence investigation conducted
by such Subscriber shall modify, limit or otherwise affect such Subscriber’s right to rely on the Company’s representations
and warranties contained in this Agreement.

 

(c) The
Subscriber is an Accredited Investor, within the meaning of Rule 501 of Regulation D promulgated under the Securities Act,
and has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks
of investing in the Company, and all information that the Subscriber has provided concerning the Subscriber, the Subscriber’s
financial position and knowledge of financial and business matters is true, correct and complete. The Subscriber acknowledges
and understands that the Company will rely on the information provided by the Subscriber in this Agreement and in the Subscriber
Questionnaire annexed hereto as Exhibit A for purposes of complying with
federal and applicable state securities laws.

 

(d) Except
as otherwise disclosed in writing by the Subscriber to the Company, the Subscriber has not dealt with a Placement Agent in connection
with the purchase of the Notes and agrees to indemnify and hold the Company and its officers and directors harmless from any claims
for Placement Agent or fees in connection with the transactions contemplated herein.

 

(e) The
Subscriber is not relying on the Company or any of its management, officers or employees with respect to any legal, investment
or tax considerations involved in the purchase, ownership and disposition of Notes or Warrants. The Subscriber has relied solely
on the advice of, or has consulted with, in regard to the legal, investment and tax considerations involved in the purchase, ownership
and disposition of Notes and Warrants, the Subscriber’s own legal counsel, business and/or investment adviser, accountant
and tax adviser.

 

(f) The
Subscriber understands that the Notes and the Warrants, or the securities into which either of them may convert or be exercised
for, cannot be sold, assigned, transferred, exchanged, hypothecated or pledged, or otherwise disposed of or encumbered except
in accordance with the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and that a market may never exist for the resale of any such securities. In addition, the Subscriber understands that the Notes,
Warrants or the securities into which they may convert or be exercised for, have not been registered under the Securities Act,
or under any applicable state securities or blue sky laws or the laws of any other jurisdiction, and cannot be resold unless they
are so registered or unless an exemption from registration is available. The Subscriber understands that there is no current plan
to register the Notes, Warrants or the securities into which they may convert or be exercised for.

 

    6

     

    

 

(g) The
Subscriber is willing and able to bear the economic and other risks of an investment in the Company for an indefinite period of
time. The Subscriber has read and understands the provisions of this Agreement.

 

(h) The
Subscriber maintains the Subscriber’s domicile and is not merely a transient or temporary resident at the residence address
shown on the signature page of this Agreement.

 

(i) The
Subscriber is not participating in the Offering as a result of or subsequent to: (i) any advertisement, article, notice or other
communication published in any newspaper, magazine or similar media or broadcast over television or radio; (ii) any seminar or
meeting whose attendees have been invited by any general solicitation or general advertising; or (iii) any registration statement
the Company may have filed with the SEC.

 

(j) If
the Subscriber is an entity, the Subscriber is duly organized, validly existing and in good standing under the laws of its jurisdiction
of incorporation or organization, as the case may be. The Subscriber has all requisite power and authority to own its properties,
to carry on its business as presently conducted, to enter into and perform the Subscription and the agreements, documents and
instruments executed, delivered and/or contemplated hereby (collectively, the “Subscription Documents”)
to which it is a party and to carry out the transactions contemplated hereby and thereby. The Subscription Documents are valid
and binding obligations of the Subscriber, enforceable against it in accordance with their terms, except as enforceability may
be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to time in effect, which
affect enforcement of creditors’ rights generally. If applicable, the execution, delivery and performance of the Subscription
Documents to which it is a party have been duly authorized by all necessary action of the Subscriber. The execution, delivery
and performance of the Subscription Documents and the performance of any transactions contemplated by the Subscription Documents
will not: (i) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under
any contract or obligation to which the Subscriber is a party or by which it or its assets are bound, or any provision of its
organizational documents (if an entity), or cause the creation of any lien or encumbrance upon any of the assets of the Subscriber;
(ii) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under, any provision
of any law, regulation or rule, or any order of, or any restriction imposed by any court or other governmental agency applicable
to the Subscriber; (iii) require from the Subscriber any notice to, declaration or filing with, or consent or approval of any
governmental authority or other third party other than pursuant to federal or state securities or blue sky laws; or (iv) accelerate
any obligation under, or give rise to a right of termination of, any agreement, permit, license or authorization to which the
Subscriber is a party or by which it is bound.

 

(k) The
Subscriber acknowledges and agrees that the Company intends to raise additional funds to operate its business and that it will
likely suffer dilution as a result thereof.

 

(l) The
Subscriber acknowledges and agrees that the Company will have broad discretion with respect to the use of the proceeds from this
Offering, and investors will be relying on the judgment of management regarding the application of these proceeds.

 

    7

     

    

 

(m) At
the time the Subscriber was offered the Notes and the Warrants, it was, and at the date hereof it is, and at each Closing and
each date on which the Subscriber converts the Notes and exercises the Warrants the Subscriber will be, an “accredited investor”
as defined in Rule 501(a) under the Securities Act. The Subscriber hereby represents that neither the Subscriber nor any of its
Rule 506(d) Related Parties is a “bad actor” within the meaning of Rule 506(d) promulgated under the Securities Act.
For purposes of this Agreement, “Rule 506(d) Related Party” shall mean a person or entity covered by
the “Bad Actor disqualification” provision of Rule 506(d) of the Securities Act.

 

(n) The
Subscriber understands the various risks of an investment in the Company, and has carefully reviewed the various risk factors
described in the Company’s filings with the SEC, including those risks listed in the Company’s Annual Report on Form
10-K for the year ended September 30, 2019.

 

3. COVENANTS
OF THE SUBSCRIBERS. 

 

3.1 Right
of First Offer. In the event that a Subscriber shall elect to sell all or any portion of a Note or Warrant held by
such Subscriber to any person or entity other than an Affiliate (as hereinafter defined), such Subscriber shall first give written
notice thereof to the Company, which notice shall set forth the original principal amount of such Note and the Warrant to be sold
and the sales price. For a period of 15 days after receipt of such notice, the Company shall have the right to purchase all or
any portion of such Note and Warrant at the so specified sales price, exercisable by giving written notice thereof to such Subscriber
within such 15-day period. In the event the Company fails to timely exercise such right, such Subscriber may, subject to Section
3.2 hereof, offer and sell such Note and Warrant at the same or a higher price for a period of 180 days after expiration of
such 15-day time period. After expiration of such 180-day period, such Subscriber shall not re-offer any of such Note or Warrant
without first allowing the Company to exercise the right herein granted.

 

3.2 Right
of First Refusal. In the event that any Subscriber shall receive and accept a bona fide offer (each, an “Offer”)
from any person or entity (other than an Affiliate (as hereinafter defined) or another original holder of Notes) to purchase all
or any portion of the Notes or Warrants of such Subscriber, such Subscriber shall give written notice thereof to the Company,
which notice shall be accompanied by a copy of such offer or a detailed description of the terms thereof (each, an “Offer
Notice”). For a period of 15 days after receipt of the Offer Notice, the Company may elect to purchase the Notes
or Warrants subject to the Offer on the same terms as are described in the Offer Notice by giving notice of such election to such
Subscriber within such 15-day period. In the event the Company fails to timely exercise such right, the Subscriber may offer and
sell such Notes or Warrants to the party delivering the Offer on the terms of such Offer.

 

For
purposes of this Agreement, the term “Affiliate” shall mean: (a) for purposes of any Subscriber that
is an individual, (i) the ancestors, descendants, spouse or private, tax-exempt foundation of such Subscriber, or (ii) a trust,
partnership, limited liability company, custodianship or other fiduciary account for the benefit of such Subscriber and/or such
private foundation, ancestors, descendants or spouse; (b) for purposes of any Subscriber that is not an individual, (i) any person
controlled by, or under the control of, the Subscriber, or (ii) any member, stockholder, partner or other equity holder of such
Subscriber that is an “accredited investor”, as that term is defined in Rule 501 of Regulation D, as promulgated under
the Securities Act.

 

    8

     

    

 

3.3 Injunctive
Relief. Each Subscriber acknowledges and agrees that any breach of the covenants contained in this Section 3
shall constitute a material breach of this Agreement and that damages would be an inadequate remedy in the event of such breach.
Accordingly, such Subscriber agrees that the Company shall be entitled to the remedy of specific performance in the event of any
such breach and hereby consents to, and waives any right to contest, the imposition of any injunction by a court of competent
jurisdiction requested by the Company to enforce specific performance of such covenants. Each Subscriber further agrees that should
such Subscriber breach any of such covenants and force the Company to obtain an injunction to specifically enforce such covenants,
such Subscriber shall reimburse the Company for all costs incurred by the Company in obtaining such injunction, including, without
limitation, court costs and reasonable attorneys’ fees and disbursements, all promptly upon receipt of an invoice therefor.

 

3.4 Termination
of Rights. The obligations of the Subscribers, and the rights of the Company, under this Section 3 shall terminate
upon the effective date of a registration statement for a firmly underwritten initial public offering of the Company’s capital
stock under the Securities Act.

 

4. MISCELLANEOUS.

 

4.1 Registration
Rights. Subject at all times to the provisions of the Note, following the earlier of (i) the final Closing of the sales
and issuance of the Notes, (ii) the final closing of a Qualified Financing, (iii) the maturity date of the Notes or (iv) the occurrence
of a Strategic Transaction (as defined in the Notes), upon the terms set forth therein, the parties hereto will enter into a Registration
Rights Agreement pursuant to which, among other things, the Company will agree to provide certain registration rights with respect
to the shares underlying the Notes and Warrants under the Securities Act and the rules and regulations promulgated thereunder
and applicable state securities laws

 

4.2 Indemnification.

 

(a) The
Subscriber will, severally and not jointly with any other Subscribers, indemnify and hold harmless the Company and its officers,
directors, members, shareholders, partners, representatives, employees and agents, successors and assigns against any losses,
obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation,
court costs, reasonable attorneys’ fees and costs of defense and investigation), amounts paid in settlement or expenses,
joint or several (collectively, “Company Claims”), reasonably incurred in investigating, preparing or
defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court
or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an
indemnified party is or may be a party thereto, to which any of them may become subject insofar as such Company Claims (or actions
or proceedings, whether commenced or threatened, in respect thereof): (i) arise out of or are based upon any untrue statement
or untrue statement of a material fact made by the Subscriber and contained in this Agreement; or (ii) arise out of or are based
upon any material breach by the Subscriber of any material representation, warranty, or agreement made by the Subscriber contained
herein; provided, however, and notwithstanding anything to the contrary, in no event shall the liability of the Subscriber pursuant
to this Section 4.2 exceed the amount of the Note that the Subscriber purchases pursuant to this Agreement.

 

    9

     

    

 

4.3 The
Company will indemnify and hold harmless each Subscriber and its officers, directors, members, shareholders, partners, representatives,
employees and agents, successors and assigns, and each other person, if any, who controls such Subscriber within the meaning of
the Securities Act against any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties,
charges, costs (including, without limitation, court costs, reasonable attorneys’ fees and costs of defense and investigation),
amounts paid in settlement or expenses, joint or several (collectively, “Subscriber Claims”), reasonably
incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken
from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether
pending or threatened, whether or not an indemnified party is or may be a party thereto, to which any of them may become subject
insofar as such Subscriber Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of
or are based upon: (i) any blue sky application or other document executed by the Company specifically for that purpose or based
upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the
Notes (or securities issuable upon conversion of the Notes) under the securities laws thereof (any such application, document
or information herein called a “Blue Sky Application”); (ii) any untrue statement or alleged untrue
statement of a material fact made by the Company in this Agreement; (iii) any breach by the Company of any representation, warranty,
or agreement made by it contained herein or in the Note; or (iv) any violation by the Company or its agents of any
rule or regulation promulgated under the Securities Act applicable to the Company or its agents and relating to action or inaction
required of the Company in connection with the Offering; and will reimburse such Subscriber, and each such officer, director or
member and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating
or defending any such claim or action; provided, however, that the Company will not be liable in any such case if and to the extent
that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement
or omission or alleged omission so made in conformity with information furnished by such Subscriber or any such controlling person
to the Company.

 

4.4 Addresses
and Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or
communication is delivered via e-mail transmission prior to 5:00 P.M., New York City time, on a trading day, (b) the next trading
day after the date of transmission, if such notice or communication is delivered via e-mail transmission on a day that is not
a trading day or later than 5:00 P.M., New York City time, on any trading day, (c) the trading day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt by
the party to whom such notice is required to be given. The address and e-mail address for such notices and communications shall
be as follows:

 

	If to the
    Company to:	 	NeuroOne
Medical Technologies Corporation 

        7599
Anagram Drive 

        Eden
Prairie, MN 55344 

        Telephone:
(952) 426-1383 

        Attention:
David A. Rosa 

        Email:
        daver@n1mtc.com

	 	 	 
	With copies to:	 	Honigman
LLP 

        650
Trade Centre Way, Suite 200

        Kalamazoo,
MI 49002

        Telephone
No.: (269) 337-7702

        Facsimile
No.: (269) 337-7703

        Attention:
Phillip D. Torrence

        E-mail:
        PTorrence@honigman.com

 

    10

     

    

 

If
to the Subscriber, to the address and e-mail address set forth on the signature page annexed hereto.

 

Any
such person may by notice given in accordance with this Section 4.4 to the other parties hereto designate another address
or person for receipt by such person of notices hereunder. 

 

4.5 Titles
and Captions. All Article and Section titles or captions in this Agreement are for convenience only. They shall not
be deemed part of this Agreement and do not in any way define, limit, extend or describe the scope or intent of any provisions
hereof.

 

4.6 Assignability.
This Agreement is not transferable or assignable by the undersigned.

 

4.7 Pronouns
and Plurals. Whenever the context may require, any pronoun used herein shall include the corresponding masculine, feminine
or neuter forms. The singular form of nouns, pronouns and verbs shall include the plural and vice versa.

 

4.8 Further
Action. The parties shall execute and deliver all documents, provide all information and take or forbear from taking
all such action as may be necessary or appropriate to achieve the purposes of this Agreement. Each party shall bear its own expenses
in connection therewith.

 

4.9 Applicable
Law. This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware without
regard to its conflict of law rules.

 

4.10 Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs,
administrators, successors, legal representatives, personal representatives, permitted transferees and permitted assigns. If the
undersigned is more than one person, the obligation of the undersigned shall be joint and several and the agreements, representations,
warranties and acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and such person’s
heirs, executors, administrators and successors.

 

    11

     

    

 

4.11 Integration.
This Agreement, together with the remainder of the Subscription Documents of which this Agreement forms a part, constitutes
the entire agreement among the parties pertaining to the subject matter hereof and supersedes and replaces all prior and contemporaneous
agreements and understandings, whether written or oral, pertaining thereto, including without limitation, the Prior Agreement.
No covenant, representation or condition not expressed in this Agreement shall affect or be deemed to interpret, change or restrict
the express provisions hereof.

 

4.12 Amendment.
 This Agreement, the Notes and the Warrants may be amended only with the written consent of the Company and the holders
of a majority of the aggregate principal amount of the Notes (a “Majority in Interest”). The conditions
or observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively
or prospectively) only by written instrument and with respect to conditions or performance obligations benefiting the Company,
by the Company, and with respect to conditions or performance obligations benefiting the Subscribers, only with the consent of
a Majority in Interest. Any amendment or waiver effected in accordance with this Section 4.12 shall be binding on all holders
of the Notes, even if they do not execute such amendment, consent or waiver, as the case may be.

 

4.13 Creditors.
 None of the provisions of this Agreement shall be for the benefit of or enforceable by creditors of any party.

 

4.14 Waiver.
 No failure by any party to insist upon the strict performance of any covenant, agreement, term or condition of this
Agreement or to exercise any right or remedy available upon a breach thereof shall constitute a waiver of any such breach or of
such or any other covenant, agreement, term or condition.

 

4.15 Rights
and Remedies. The rights and remedies of each of the parties hereunder shall be mutually exclusive, and the implementation
of one or more of the provisions of this Agreement shall not preclude the implementation of any other provision.

 

4.16 Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of
this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. In the event that
any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

Signatures
on the Following Pages

 

    12

     

    

 

As
of the date first written above, Subscriber hereby elects to purchase Notes in an aggregate subscription amount of $____________________
(NOTE: to be completed by Subscriber) and executes the Subscription Agreement.

 

	Signature
                                         of Subscriber:

         

        ___________________________________ 

        Name:
        ______________________________

        Title
        (if entity): ________________________

          

        SSN
        or EIN: _________________________

          

        Mailing
        Address of Subscriber:

         

        ___________________________________

        ___________________________________

        ___________________________________

         

        E-mail
        Address: _______________________ 
	 	 

         

        __________________________________ 

        Print
        Name of Subscriber

         

         

         

         

        Residence
        of Subscriber

        (if
        different from Mailing Address)

        ___________________________________

        ___________________________________

        ___________________________________ 

         

 

	If
    Joint Ownership, check one:	 
	 	 
	☐
     Joint Tenants with Right of Survivorship	 
	☐
     Tenants-in-Common
        ☐
         Tenants by the Entirety
	 
	☐
     Community Property	 
	☐
                                          Other (specify): ______________________

         

         

        Joint
        Owner (if applicable):

         

        ___________________________________

        Name:
        ______________________________
	 

 

Signature
Page to Subscription Agreement

     

     

    

 

FOREGOING
SUBSCRIPTION ACCEPTED:

 

	NeuroOne
    Medical Technologies Corporation	 
	 	 	 
	By:	        	 
	Name:	David A. Rosa	 
	Title:	Chief Executive Officer and President	 

 

 

Signature
Page to Subscription Agreement

     

     

    

 

Exhibit
A

 

NEUROONE
MEDICAL TECHNOLOGIES CORPORATION

 

SUBSCRIBER
QUESTIONNAIRE

 

NeuroOne
Medical Technologies Corporation

7599
Anagram Drive

Eden Prairie, MN 55344 

 

The
information contained herein is being furnished to NeuroOne Medical Technologies Corporation (the “Company”)
in order for the Company to determine whether the undersigned’s subscription for Convertible Promissory Notes (the “Notes”)
and Warrants (the “Warrants”) therein may be accepted pursuant to Section 4(a)(2) of the Securities
Act of 1933, as amended (the “Securities Act”) and Regulation D promulgated thereunder (“Regulation
D”). The undersigned understands that (i) the Company will rely upon the following information for purposes of complying
with Federal and applicable state securities laws, (ii) none of the Notes, the Warrants or any securities issuable thereunder
will be registered under the Securities Act in reliance upon the exemption from registration provided by Section 4(a)(2) of the
Securities Act and Regulation D, and (iii) this questionnaire is not an offer to sell nor the solicitation of an offer to
buy any Notes, Warrants or any other securities, to the undersigned.

 

The
following representations and information are furnished herewith:

 

1. Qualification
as an Accredited Investor. Please check the categories applicable to you indicating the basis upon which you qualify
as an Accredited Investor for purposes of the Securities Act and Regulation D thereunder.

 

	☐	Individual
    with Net Worth In Excess of $1,000,000.  A natural person (not an entity) whose net worth, or joint net worth with
    his or her spouse, at the time of purchase exceeds $1,000,000. (Explanation: In calculating your net worth, you must exclude
    the value of your primary residence. This means you must exclude both the equity in your primary residence and any mortgage
    or other debt secured by your primary residence up to the fair market value of your primary residence; provided, however,
    that any indebtedness secured by your primary residence that (i) you have incurred in the 60 day period prior to the date
    of your subscription to the Company or (ii) is in excess of the fair market value of your primary residence should be considered
    a liability and deducted from your aggregate net worth. In calculating your net worth, you may include your equity in personal
    property and real estate (excluding your primary residence), cash, short-term investments, stock and securities. Your inclusion
    of equity in personal property and real estate (excluding your primary residence) should be based on the fair market value
    of such property less debt secured by such property.)
	 	 
	☐	Individual
    with a $200,000 Individual Annual Income.  A natural person (not an entity) who had an individual income of
    more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income
    level in the current year.

 

    A-1

     

    

 

	☐	Individual
    with a $300,000 Joint Annual Income.  A natural person (not an entity) who had joint income with his or her
    spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the
    same income level in the current year.
	 	 
	☐	Corporations
    or Partnerships.  A corporation, partnership, or similar entity that has in excess of $5,000,000 of assets and
    was not formed for the specific purpose of acquiring Notes and Warrants in the Company.
	 	 
	☐	Revocable
    Trust.  A trust that is revocable by its grantors and each of whose grantors is an accredited investor.  (If
    this category is checked, please also check the additional category or categories under which the grantor qualifies as an
    accredited investor.)
	 	 
	☐	Irrevocable
    Trust.  A trust (other than an ERISA plan) that (i) is not revocable by its grantors, (ii) has in excess of
    $5,000,000 of assets, (iii) was not formed for the specific purpose of acquiring Notes and Warrants, and (iv) is directed
    by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating
    the merits and risks of an investment in the Company.
	 	 
	☐	IRA
    or Similar Benefit Plan.  An IRA, Keogh or similar benefit plan that covers a natural person who is an accredited
    investor. (If this category is checked, please also check the additional category or categories under which the natural person
    covered by the IRA or plan qualifies as an accredited investor.)
	 	 
	☐	Participant-Directed
    Employee Benefit Plan Account.  A participant-directed employee benefit plan investing at the direction of,
    and for the account of, a participant who is an accredited investor.  (If this category is checked, please also
    check the additional category or categories under which the participant qualifies as an accredited investor.)
	 	 
	☐	Other
    ERISA Plan.  An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed
    plan with total assets in excess of $5,000,000 or for which investment decisions (including the decision to purchase
    an Interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.
	 	 
	☐	Government
    Benefit Plan.  A plan established and maintained by a state, municipality, or any agency of a state or municipality,
    for the benefit of its employees, with total assets in excess of $5,000,000.
	 	 
	☐	Non-Profit
    Entity.  An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total
    assets in excess of $5,000,000 (including endowment, annuity and life income funds), as shown by the organization’s
    most recent audited financial statements.

 

    A-2

     

    

 

	☐	Other Institutional Investor (check one).  
	 	 	 
	 	☐ 	A
    bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity);
	 	☐	A
    savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting
    for its own account or in a fiduciary capacity;
	 	☐ 	A
    Placement Agent-dealer registered under the Securities Exchange Act of 1934, as amended;
	 	☐ 	An
    insurance company, as defined in section 2(13) of the Securities Act;  
	 	☐ 	A
    “business development company,” as defined in Section 2(a)(48) of the Investment Company Act;  
	 	☐ 	A
    small business investment company licensed under Section 301(c) or (d) of the Small Business Investment Act of 1958, as amended;
    or
	 	☐ 	A
    “private business development company” as defined in Section 202(a)(22) of the Investment Advisers Act of 1940,
    as amended.

 

	☐	Executive
    Officer or Director.  A natural person who is an executive officer, director or managing member of the Company.
	 	 
	☐	Entity
    Owned Entirely By Accredited Investors.  A corporation, partnership, private investment company or similar entity
    each of whose equity owners is an accredited investor.  (If this category is checked, please also check the
    additional category or categories under which each equity owner qualifies as an accredited investor.)
	 	 
	☐	I
    do not qualify for any of the above. 

 

2. Representations
and Warranties by Limited Liability Companies, Corporations, Partnerships, Trusts and Estates. If the Subscriber is
a corporation, partnership, limited liability company or trust, the Subscriber and each person signing on behalf of Subscriber
certifies that the following responses are accurate and complete:

 

	 	 	Was
    the undersigned organized or reorganized for the specific purpose, or for the purpose among other purposes, of acquiring interests
    in the Company?
	 	 	 
	 	 	Yes☐	No☐
	 	 	 	 
	 	 	Will
    the Subscriber, at any time, invest more than 40% of Subscriber’s assets in the Company?
	 	 	 
	 	 	Yes☐	No☐
	 	 	 	 
	 	 	Under
    the Subscribing entity’s governing documents and in practice, are the Subscribing entity’s investment decisions
    based on the investment objectives of the Subscribing entity and its owners generally and not on the particular investment
    objectives of any one or more of its individual owners?
	 	 	 
	 	 	Yes☐	No☐

 

    A-3

     

    

 

	 	 	Does
    any individual shareholder, partner or member or group of shareholders, partners or members of the undersigned have the right
    to elect whether or not to participate in the investment of the Subscribing entity in the Company or to determine the level
    of participation of such partner or group therein?
	 	 	 
	 	 	Yes☐	No☐
	 	 	 	 
	 	 	Is
    the Subscribing entity authorized and qualified to become a note holder of the Company and does the Subscribing entity and
    the undersigned hereto further represent and warrant that such signatory has been duly authorized by the Subscribing entity
    to execute the Subscription Documents?
	 	 	 
	 	 	Yes☐	No☐
	 	 	 	 
	 	 	Is
    the undersigned a private investment company which is not registered under the Investment Company Act, as amended, in reliance
    on Section 3(c)(1) or Section 3(c)(7) thereof?
	 	 	 
	 	 	Yes☐	No☐

 

3. Taxpayer
ID Number; No Backup Withholding; Not a Foreign Person or Entity. If Subscriber is a “non-U.S. person or entity,”
allocations of Company income may be subject to withholding and taxation under the Internal Revenue Code, as amended (“Code”).
Subscriber acknowledges that it may be required to file U.S. income tax returns. If the Subscriber is a foreign corporation, foreign
partnership, foreign trust or foreign estate (as those terms are defined in the Code and the regulations thereunder), please contact
the Company. The Subscriber understands that the information contained in this item may be disclosed to the Internal Revenue Service
by the Company and that any false statement contained in this item could be punished by fine, imprisonment or both.

 

	 	 	Subscriber
    certifies that the taxpayer identification number being supplied herewith by Subscriber is Subscriber’s correct taxpayer
    identification number and that Subscriber is not subject to backup withholding under Section 3406 of the Code and the regulations
    thereunder?
	 	 	 
	 	 	Yes☐	No☐
	 	 	 	 
	 	 	Subscriber
    certifies that Subscriber is not a “Non-U.S. person” or, if an entity, that Subscribing entity is not a foreign
    corporation, foreign partnership, foreign trust or foreign estate, as those terms are defined the Code and the regulations
    thereunder.
	 	 	 
	 	 	Yes☐	No☐
	 	 	 	 
	 	 	If
    Subscriber’s non-foreign status changes or if any other information in this item changes, Subscriber agrees to notify
    the Company within 30 days thereafter.
	 	 	 
	 	 	Yes☐	No☐

 

    A-4

     

    

 

To
the best of my information and belief, the above information supplied by me is true and correct in all respects.

 

	 	By:

        
	       
	 	Name:	 
	 	Title:	 

 

 

A-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]